SAMHSA-Certified Drug Treatment Programs: What Certification Means

SAMHSA certification is a formal federal recognition process administered by the Substance Abuse and Mental Health Services Administration that applies specifically to opioid treatment programs operating in the United States. This page explains what that certification designates, how the approval process functions, which program types are subject to it, and how SAMHSA certification relates to—but differs from—broader rehab accreditation and licensing frameworks. Understanding these distinctions matters because the certification status of a program determines which controlled medications it may legally dispense, under what federal oversight structure, and according to which clinical standards.

Definition and scope

SAMHSA certification, as defined under 42 CFR Part 8, applies exclusively to Opioid Treatment Programs (OTPs) — facilities that dispense opioid agonist medications such as methadone or buprenorphine to individuals diagnosed with opioid use disorder. Under that regulation, no OTP may operate legally in the United States without SAMHSA certification, a valid Drug Enforcement Administration (DEA) registration, and state authority approval.

The term "SAMHSA-certified" is therefore narrower than it might appear. It does not apply generically to all substance use disorder treatment facilities. A residential inpatient program, a detox unit, or a behavioral health clinic that does not dispense Schedule II opioid agonist medications falls outside the Part 8 certification requirement, even if that facility receives SAMHSA block grant funding or lists itself in SAMHSA's public treatment locator (SAMHSA Treatment Locator).

The scope distinction matters practically. Facilities listed in SAMHSA's National Survey of Substance Abuse Treatment Services (N-SSATS) have self-reported their services but are not necessarily certified under 42 CFR Part 8. Only programs dispensing methadone for opioid use disorder are required to hold that certification. For methadone treatment clinics, Part 8 certification is not optional — it is a legal prerequisite for operation.

Note: The Controlled Substances Act definitions relevant to opioid treatment program classifications were amended effective December 23, 2024, to correct a technical error in the statutory definitions. Programs should confirm that internal compliance documentation and clinical protocols reflect the corrected definitional language as currently codified.

How it works

The certification process under 42 CFR Part 8 involves a sequential, multi-agency review rather than a single application to one body. The process follows these discrete phases:

1. State authority notification and approval. The OTP applicant must obtain approval from the designated state authority (DSA) in the state where the program will operate. Each state's DSA has independent authority to impose standards that exceed federal minimums.
2. Accreditation by a SAMHSA-approved accreditation body. The OTP must be accredited by one of the bodies approved by SAMHSA under 42 CFR §8.4, which include the Joint Commission, CARF International, the Commission on Accreditation of Rehabilitation Facilities, and the Commission on Accreditation for the American Osteopathic Association (SAMHSA OTP Accreditation). Accreditation reviews program governance, clinical protocols, medication security, and patient record standards.
3. DEA registration. OTPs must hold a valid DEA Schedule II practitioner registration to handle methadone and, in certain configurations, buprenorphine under 21 USC §823.
4. SAMHSA certification application and review. Following state approval and accreditation, the program submits a certification application to SAMHSA's Division of Pharmacologic Therapies (DPT). SAMHSA reviews the application and may conduct site inspections.
5. Ongoing compliance and re-accreditation. Certification is not permanent. Programs undergo re-accreditation on a cycle set by the accrediting body (typically 3 years for the Joint Commission) and are subject to federal and state inspections.

This layered structure is intentional. Opioid treatment program regulations create overlapping federal and state jurisdiction specifically because opioid agonist medications carry diversion risk under the Controlled Substances Act. A technical correction to the Controlled Substances Act definitions was enacted effective December 23, 2024; programs should verify that their DEA registration documentation and internal classification procedures align with the corrected statutory language now in effect.

Common scenarios

Three operational scenarios illustrate where SAMHSA certification is and is not in play:

Scenario 1: A standalone methadone clinic. A freestanding OTP dispensing methadone for opioid use disorder is the paradigmatic case requiring Part 8 certification. Without it, operation is a federal violation. The clinic must maintain certified status continuously, meaning a lapse in accreditation can trigger SAMHSA action to suspend or revoke certification.

Scenario 2: A hospital-based opioid treatment program. Hospital systems that operate embedded OTPs — dispensing methadone on-site to registered patients — must also hold individual OTP certification for that program component. The hospital's broader Joint Commission accreditation does not substitute for Part 8 OTP certification. This distinction is directly relevant when evaluating inpatient rehab medical services that include medication-assisted protocols.

Scenario 3: A buprenorphine-prescribing outpatient practice. Under the Consolidated Appropriations Act of 2023, DEA-registered practitioners may prescribe buprenorphine for opioid use disorder without a separate DATA waiver. However, if a program dispenses (rather than prescribes) buprenorphine — meaning patients consume doses on-site rather than taking a prescription to a pharmacy — that dispensing activity may trigger OTP certification requirements under 42 CFR Part 8. This boundary is technically complex and governed by the specific formulation and dispensing mechanism. Programs should also be aware that the December 23, 2024 technical correction to the Controlled Substances Act definitions may affect how buprenorphine dispensing arrangements are classified under the statute, and should confirm their compliance documentation reflects the corrected definitional language currently in effect. A fuller treatment of buprenorphine's regulatory status is at buprenorphine suboxone treatment.

Decision boundaries

Certification status under 42 CFR Part 8 creates concrete operational and clinical boundaries:

• What certified OTPs may do that uncertified programs cannot: Dispense methadone for opioid use disorder. Under federal law, methadone for this indication cannot be prescribed at a retail pharmacy — it must be administered or dispensed through a certified OTP (21 CFR §291.505).
• Certification vs. accreditation: Accreditation (by the Joint Commission or CARF) is a component of the certification process, not a synonym for it. A facility can be CARF-accredited without being SAMHSA-certified if it does not operate as an OTP. The relationship between these frameworks is covered in depth at joint commission carf accreditation.
• Certification vs. licensure: State licensure is a separate requirement governed by each state's behavioral health licensing board. A program must hold valid state licensure, SAMHSA certification (if an OTP), and DEA registration simultaneously — these are parallel requirements, not substitutes.
• SAMHSA listing vs. SAMHSA certification: Appearing in the SAMHSA treatment locator does not indicate OTP certification. The locator draws from N-SSATS self-reported data and includes residential, outpatient, and hospital-based programs of all types. Certification status must be verified independently through state authorities or SAMHSA's Division of Pharmacologic Therapies.
• Controlled Substances Act definitions: A technical correction to the Controlled Substances Act definitions was enacted on December 23, 2024. While this amendment addresses a drafting error rather than a substantive policy change, programs relying on specific statutory definitions for classification or compliance purposes should confirm their documentation reflects the corrected language now in effect.

For programs offering medication-assisted treatment but not dispensing opioid agonists on-site, the applicable regulatory framework differs substantially — see medication-assisted treatment overview and levels of care asam criteria for those frameworks.

References

• 42 CFR Part 8 — Certification of Opioid Treatment Programs (eCFR)
• SAMHSA — Become an Accredited Opioid Treatment Program
• SAMHSA FINDTREATMENT.GOV — Treatment Locator
• 21 CFR §291.505 — Narcotic Treatment Programs (eCFR)
• 21 USC §823 — DEA Registration Requirements (House.gov)
• SAMHSA National Survey of Substance Abuse Treatment Services (N-SSATS)
• DEA Diversion Control Division — Narcotic Treatment Programs
• Controlled Substances Act — Technical Correction to Definitions (enacted December 23, 2024)